New hope for recurrent glioblastoma? drug combo enters early trial

NCT ID NCT05039281

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. Only 6 participants are being enrolled to start.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and cabozantinib
What this could lead to: If it works, this could offer a new treatment option to control recurrent glioblastoma, potentially slowing tumor growth and extending survival.
What could go wrong: This is a very early, small trial (only 6 participants) focused on safety and dosing. The combination may not shrink tumors or improve survival, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA RECURRENT GLIOSARCOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.